Zorbium™ (buprenorphine transdermal solution) for cats
For optimal recovery from surgery, continuous pain management for feline patients is required until pain is resolved.1 One in-clinic dose of Zorbium provides four days of continuous post-op pain control for at-home comfort.
Why Choose Zorbium?
Administered once in-clinic, Zorbium removes the need to administer repeat injections or dispense buprenorphine during the critical first few days after surgery. Zorbium also reduces the challenges of administering pain medications at home and helps limit the risk of opioid misuse by pet owners.
- The only FDA-approved long-acting transdermal buprenorphine for cats
- Delivers four days of reliable pain relief from a single in-clinic dose
- Provides reassurance to veterinarians and pet owners
- Pre-dosed tubes simplify recordkeeping and disposal of controlled substances
Zorbium Dosing information
|Single use, unit dose applicator tubes - For smaller cats|
|Body weight (lbs.) - 2.6 to 6.6|
|Dose of buprenorphine - 8 mg|
|Volume of Zorbium - 0.4 mL|
|Single use, unit dose applicator tubes - For larger cats|
|Body weight (lbs.) - >6.6 to 16.5|
|Dose of buprenorphine - 20 mg|
|Volume of Zorbium - 1 mL|
Innovative, long-acting technology and convenient dosing
Applied transdermally, Zorbium continually releases buprenorphine into systemic circulation for 4 days. A user safety study confirmed no risk to adults or children with direct exposure to dry application site (30 minutes). Wear impermeable latex or nitrile gloves, protective glasses and a laboratory coat when applying Zorbium
- Step 1
Apply one to two hours before surgery
- Step 2
Fur should not be clipped
- Step 3
Do not come into direct contact with Zorbium
How to order Zorbium
To discover how you can incorporate Zorbium into your feline surgical protocol today, contact your local Elanco rep or distributor rep. Call Elanco at 1-888-545-5973.
ZORBIUM is indicated for the control of postoperative pain associated with surgical procedures in cats.
Important Safety Information
Before using ZORBIUM (buprenorphine transdermal solution), read the entire package insert including the Boxed Human Warning.
ZORBIUM contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering and disposing of ZORBIUM. Serious, life-threatening or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ZORBIUM. ZORBIUM should only be administered by veterinarians or veterinarian technicians who are trained in the handling of potent opioids. Accidental exposure to even one tube of ZORBIUM, especially in children, can result in a fatal overdose.
ZORBIUM is for topical application in cats only. Do not come into direct contact with ZORBIUM. Wear impermeable latex or nitrile gloves, protective glasses and a laboratory coat when applying ZORBIUM. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site. Do not administer to cats with a known hypersensitivity to buprenorphine hydrochloride, any inactive ingredients of ZORBIUM, or known intolerance to opioids. Do not apply ZORBIUM if the application site at the dorsal cervical area has diseased or injured skin, or to anatomic areas other than the dorsal cervical area because absorption characteristics may be different. Body temperature should be monitored postoperatively. Most common adverse reactions during anesthesia were hypothermia, hypotension and hypertension, and after anesthetic recovery were hypothermia, hyperthermia and sedation. The safe use of ZORBIUM has not been evaluated in debilitated cats; those with renal, hepatic, cardiac or respiratory disease; pregnant, lactating or breeding cats; in cats younger than four months old; or in cats <2.6 lbs. or >16.5 lbs.